ConductScience.org, home

Paper · 42225068

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,653,681Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.Cell Rep2016https://conductscience.org/library/papers/27653681PubMed
239,468,210The present and future of the Cancer Dependency Map.Nat Rev Cancer2025https://conductscience.org/library/papers/39468210PubMed
340,223,602Integration of Organoids With CRISPR Screens: A Narrative Review.Biol Cell2025https://conductscience.org/library/papers/40223602PubMed
440,035,511Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.J Med Chem2025https://conductscience.org/library/papers/40035511PubMed
530,674,557JACKS: joint analysis of CRISPR/Cas9 knockout screens.Genome Res2019https://conductscience.org/library/papers/30674557PubMed
637,436,979An organoid-based CRISPR-Cas9 screen for regulators of intestinal epithelial maturation and cell fate.Sci Adv2023https://conductscience.org/library/papers/37436979PubMed
723,550,210Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.Sci Signal2013https://conductscience.org/library/papers/23550210PubMed
826,653,891MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data.Genome Biol2015https://conductscience.org/library/papers/26653891PubMed
939,227,068FGA influences invasion and metastasis of hepatocellular carcinoma through the PI3K/AKT pathway.Aging (Albany NY)2024https://conductscience.org/library/papers/39227068PubMed
1037,552,839MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.Cancer Discov2023https://conductscience.org/library/papers/37552839PubMed
1134,529,489The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.Science2021https://conductscience.org/library/papers/34529489PubMed
1228,530,655A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo.Nat Methods2017https://conductscience.org/library/papers/28530655PubMed
1321,376,230Hallmarks of cancer: the next generation.Cell2011https://conductscience.org/library/papers/21376230PubMed
1431,712,683Synthetic lethality as an engine for cancer drug target discovery.Nat Rev Drug Discov2020https://conductscience.org/library/papers/31712683PubMed
1536,228,090Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer.Mol Cancer Ther2023https://conductscience.org/library/papers/36228090PubMed
1628,691,904Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts.Elife2017https://conductscience.org/library/papers/28691904PubMed
1737,286,821Genome-wide pooled CRISPR screening in neurospheres.Nat Protoc2023https://conductscience.org/library/papers/37286821PubMed
1824,794,707MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.Cancer Cell2014https://conductscience.org/library/papers/24794707PubMed
1937,668,528Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal.Cancer Res2023https://conductscience.org/library/papers/37668528PubMed
2028,993,443CRISPR/Cas9 screening using unique molecular identifiers.Mol Syst Biol2017https://conductscience.org/library/papers/28993443PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/42225068/references